Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05265325 · ClinicalTrials.gov registry record · Phase 2
A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
A Phase 2 study, sponsored by Kind Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT05265325: Completed Phase 2 study, sponsored by Kind Pharmaceuticals.
NCT05265325 is a Phase 2 study that has completed, run by Kind Pharmaceuticals. The registered enrollment target is 175 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05265325, a Phase 2 study, has completed, sponsored by Kind Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
This is a phase II study to evaluate the safety and efficacy of AND017 in renal anemia patients on dialysis
Primary Outcome
Incidence of adverse events
Interventions
- DRUG AND017 capsules TIW
- DRUG AND017 capsules QW
- DRUG epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2023-05-03 |
| Est. Completion | 2024-04-25 |
| Phase | Phase 2 |
What the finished NCT05265325 record still lists
NCT05265325 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher).
The record links to 0 conditions, and to 3 interventions - of which AND017 capsules TIW is the first listed.
NCT05265325 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05265325 about?
NCT05265325 is a clinical study titled "A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis". This is a phase II study to evaluate the safety and efficacy of AND017 in renal anemia patients on dialysis
What is the current status of trial NCT05265325?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2023-05-03. Estimated completion is 2024-04-25.
What interventions are being tested in trial NCT05265325?
The interventions under investigation include: AND017 capsules TIW (DRUG), AND017 capsules QW (DRUG), epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars (DRUG).
Who is sponsoring clinical trial NCT05265325?
This trial is sponsored by Kind Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05265325's enrollment target sits among peer trials
175 396th of 2000 higher than 1,605 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI